![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BioSante Completes Pivotal Phase III Clinical Trial for Estrogen Gel
BioSante Completes Pivotal Phase III Clinical Trial for Estrogen Gel
BioSante Pharmaceuticals has completed its 12-week, pivotal Phase III clinical trial to evaluate the safety and efficacy of Bio-E-Gel for the treatment of moderate-to-severe hot flashes in menopausal women.
BioSante's multicenter, randomized, double-blind, placebo-controlled trial of Bio-E-Gel (bioidentical estradiol transdermal gel) was conducted in the U.S. and Canada. Current FDA requirements for approval of new estradiol products include one 12-week Phase III clinical trial. The study included three doses of Bio-E-Gel to maximize the safety profile by identifying the lowest effective dose.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct